IBRX vs. HALO, RVMD, EXEL, CRSP, KRYS, IMVT, PCVX, SWTX, IOVA, and DNLI
Should you be buying ImmunityBio stock or one of its competitors? The main competitors of ImmunityBio include Halozyme Therapeutics (HALO), Revolution Medicines (RVMD), Exelixis (EXEL), CRISPR Therapeutics (CRSP), Krystal Biotech (KRYS), Immunovant (IMVT), Vaxcyte (PCVX), SpringWorks Therapeutics (SWTX), Iovance Biotherapeutics (IOVA), and Denali Therapeutics (DNLI). These companies are all part of the "biological products, except diagnostic" industry.
Halozyme Therapeutics (NASDAQ:HALO) and ImmunityBio (NASDAQ:IBRX) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, community ranking, analyst recommendations and valuation.
In the previous week, Halozyme Therapeutics had 1 more articles in the media than ImmunityBio. MarketBeat recorded 6 mentions for Halozyme Therapeutics and 5 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 1.19 beat Halozyme Therapeutics' score of -0.07 indicating that Halozyme Therapeutics is being referred to more favorably in the media.
Halozyme Therapeutics has a net margin of 36.94% compared to Halozyme Therapeutics' net margin of -198,994.05%. ImmunityBio's return on equity of 225.71% beat Halozyme Therapeutics' return on equity.
Halozyme Therapeutics has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.
Halozyme Therapeutics received 499 more outperform votes than ImmunityBio when rated by MarketBeat users. Likewise, 69.15% of users gave Halozyme Therapeutics an outperform vote while only 13.04% of users gave ImmunityBio an outperform vote.
Halozyme Therapeutics currently has a consensus price target of $53.14, indicating a potential upside of 18.86%. ImmunityBio has a consensus price target of $6.00, indicating a potential downside of 21.57%. Given ImmunityBio's stronger consensus rating and higher probable upside, equities research analysts clearly believe Halozyme Therapeutics is more favorable than ImmunityBio.
Halozyme Therapeutics has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Comparatively, ImmunityBio has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500.
97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 8.6% of ImmunityBio shares are owned by institutional investors. 2.4% of Halozyme Therapeutics shares are owned by company insiders. Comparatively, 83.4% of ImmunityBio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Halozyme Therapeutics beats ImmunityBio on 16 of the 18 factors compared between the two stocks.
Get ImmunityBio News Delivered to You Automatically
Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImmunityBio Competitors List
Related Companies and Tools
